S100A4 and colorectal carcinoma: Based on the two large, unselected patient cohorts in the present report, we conclude that nuclear S100A4 is established as a biomarker of poor outcome in stage II and III CRC, and that further studies to investigate its prognostic role in this patient group are not needed.